PRA Holdings, Inc. Announces Submission of Draft Registration Statement for Initial Public Offering
PRA Holdings, Inc. ("PRA") announced today that it has submitted a confidential draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission (the "SEC") for a possible initial public offering of shares of its common stock (the "Proposed IPO"). The number of shares to be offered and the price range for the offering have not yet been determined.
PRA intends to use the proceeds from the Proposed IPO to reduce outstanding borrowings under its credit facilities, provide liquidity for existing shareholders, pay certain fees and expenses, and for working capital and general corporate purposes. The initial public offering is expected to commence after the SEC completes the review process initiated by PRA's confidential submission of its draft registration statement, subject to market conditions and other conditions.
This announcement is being made pursuant to and in accordance with Rule 135 under the U.S. Securities Act of 1933, as amended. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
